Bridging the Gap in Cancer Care with AI: From Validation to Vital Infrastructure
February 4th is World Cancer Day, an initiative led by the Union for International Cancer Control (UICC). The overarching theme for this multi-year campaign is "Close the Care Gap."
Access to life-saving cancer screening should not be determined by your postal code, income, or available local resources. Yet, the reality is that significant disparities exist in diagnostic quality and access depending on where a patient lives.
To mark this important day, Coreline Soft is proud to release the
[2025 Impact Report]. This report details our journey in using AI technology to reduce these disparities and establish a new global standard for lung cancer screening.
1. Standardization: The Key to Equity
In lung cancer screening, consistency is paramount. However, the global shortage of radiologists coupled with exploding screening volumes creates a bottleneck. This can lead to variability in reading quality between top-tier university hospitals and smaller regional centers.
Coreline Soft’s AI solution, AVIEW, acts as a "Digital Medical Infrastructure" that bridges this gap.
•
Standardized Quality: AVIEW provides quantitative analysis that supports consistent reading quality, ensuring patients receive the same high standard of care whether they are in a rural clinic or a major metropolitan hospital.
•
Workflow Efficiency: By automating repetitive analysis tasks, AI allows medical professionals to focus on complex decision-making and patient counseling. Clinical evidence from the UKLS and MILD trials suggests AVIEW can improve reading efficiency by up to 79% and 71%, respectively.
By enabling "
Standardized Screening Everywhere," we are using technology to directly address the root causes of the care gap.
2. 2.5 Million Scans: Trust Built on Scale
The true value of AI in healthcare is proven not in a lab, but by its stability in diverse, real-world clinical environments. As of 2025, Coreline Soft has surpassed a cumulative total of 2.5 million analysis cases.
The 2025 Impact Report showcases the real-world impact of AVIEW across 19 countries and 500+ clinical sites:
•
Partner for National Screening: Beyond Korea (KNLCS), we have been selected as the official solution for major European lung cancer screening projects in Germany (HANSE), France (IMPULSION), and Italy (RISP).
•
Regulatory Excellence: With full clearances from the US FDA and EU CE (MDR), we have demonstrated both technical safety and clinical validity on a global stage.
3. Beyond Detection to Prevention: The 2026 Vision
Closing the care gap also means shifting the paradigm from "treating illness" to "preserving health." In this report, we unveil our roadmap for the Future of Thoracic Care in 2026.
Our vision is "One CT, Comprehensive Insight." By utilizing a single Low-Dose CT (LDCT) scan to simultaneously analyze not just lung nodules, but also COPD (Emphysema) and Cardiovascular Disease (Coronary Calcium), we aim to provide a comprehensive Thoracic Care Suite. This approach transforms screening into a proactive tool for preventive population health management.
[Download Report] See the Future of AI Screening
Curious how AI is becoming the vital infrastructure for a more equitable healthcare system? Download the full 2025 Impact Report to explore the clinical evidence and strategic roadmap driving this change.
Inside the Report:
•
Global Impact: Deployment strategies across 19 countries & 500 sites
•
Clinical Evidence: Data supporting efficiency gains and diagnostic consistency
•
Future Roadmap: The 2026 strategy for comprehensive Thoracic Care
[Download the 2025 Impact Report]
List
